한글목차

암 유병률의 증가와 전문적인 영양 지원에 대한 수요에 힘입어 세계 종양학 영양 시장은 큰 성장을 이룰 것입니다. 종양학 영양 시장 규모는 2025년 28억 3,000만 달러에서 2032년까지 8.60%의 CAGR로 2032년까지 50억 4,000만 달러에 달할 것으로 예상됩니다. 암 치료의 발전과 환자 치료에서 영양의 역할에 대한 인식이 높아짐에 따라 이 시장은 유망한 궤도에 올라서고 있습니다.

종양학 영양은 암 치료를 받고 있는 환자들의 특별한 식생활 요구를 충족시키기 위한 헬스케어 산업의 전문 분야입니다. 암 치료는 종종 영양 부족, 체중 감소, 면역력 저하 등의 문제를 야기합니다. 종양학 영양은 개별화된 영양 전략을 통해 이러한 영향을 완화하고, 환자의 삶의 질을 향상시키며, 치료 결과를 지원하는 것을 목표로 합니다.

전 세계적으로 암 발병률이 증가함에 따라 치료 결과를 개선하고 치료와 관련된 부작용을 관리하기 위해 환자 맞춤형 영양 지원의 필요성이 강조되고 있습니다. 면역요법 및 화학요법과 같은 치료법의 발전으로 보완적인 영양 전략에 대한 수요가 증가하고 있습니다. 표적화된 보충제 및 면역 지원 성분을 포함한 영양 제제의 혁신으로 종양학 영양의 범위가 넓어졌습니다. 의료진과 환자들은 영양이 치료 효과와 전반적인 웰빙에 미치는 영향에 대해 점점 더 많이 인식하고 있습니다.

세계의 종양학 영양 시장에 대해 조사했으며, 시장 개요와 함께 암 종류별, 최종 용도별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등의 정보를 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 경제 개요
• PESTLE 분석

제3장 세계의 종양학 영양 시장 전망, 2019-2032년

• 세계의 종양학 영양 시장 전망, 암 유형별, 금액(10억 달러), 2019-2032년
• 세계의 종양학 영양 시장 전망, 최종 용도별, 금액(10억 달러), 2019-2032년
• 세계의 종양학 영양 시장 전망, 지역별, 금액(10억 달러), 2019-2032년

제4장 북미의 종양학 영양 시장 전망, 2019-2032년

제5장 유럽의 종양학 영양 시장 전망, 2019-2032년

제6장 아시아태평양의 종양학 영양 시장 전망, 2019-2032년

제7장 라틴아메리카의 종양학 영양 시장 전망, 2019-2032년

제8장 중동 및 아프리카의 종양학 영양 시장 전망, 2019-2032년

제9장 경쟁 구도

• 기업 시장 점유율 분석, 2025년
• 경쟁 대시보드
• 기업 개요
  • Aceto
  • B. Braun Melsungen AG
  • Baxter
  • Fresenius Kabi AG
  • Hormel Foods Corporation
  • Mead Johnson & Company, LLC
  • Meiji Holdings Co., Ltd
  • Nestle S.A.
  • BioSig Technologies, Inc.
  • Auris Health, Inc.
  • 기타

제10장 부록

영문목차

The global oncology nutrition market is set to experience significant growth, driven by the increasing prevalence of cancer and the demand for specialized nutritional support. The oncology nutrition market is projected to reach a valuation of $2.83 billion in 2025 and expand further to $5.04 billion by 2032, at a CAGR of 8.60%. With advancements in cancer treatments and a heightened awareness of the role of nutrition in patient care, this market is on a promising trajectory.

Market Insights Oncology nutrition is a specialized segment of the healthcare industry dedicated to addressing the unique dietary needs of individuals undergoing cancer treatment. Cancer therapies often result in challenges such as malnutrition, weight loss, and weakened immune systems. Oncology nutrition aims to mitigate these effects through personalized nutritional strategies, improving patients' quality of life and supporting treatment outcomes.

Key Growth Drivers

• 1. Rising Cancer Prevalence: The increasing global burden of cancer underscores the need for tailored nutritional support to enhance treatment outcomes and manage therapy-related side effects.
• 2. Advancements in Cancer Treatments: Progress in therapies like immunotherapy and chemotherapy has elevated the demand for complementary nutritional strategies.
• 3. Focus on Research and Development: Innovations in nutritional formulations, including targeted supplements and immune-supportive ingredients, have expanded the scope of oncology nutrition.
• 4. Awareness of Nutrition's Role: Healthcare providers and patients are increasingly recognizing the impact of nutrition on treatment efficacy and overall well-being.

Business Opportunities

• 1. Digital Health Solutions and Remote Monitoring: The integration of telehealth platforms and mobile applications presents opportunities for real-time nutritional support and patient monitoring, enhancing accessibility and convenience.
• 2. Personalized Nutrition Products: The development of tailored supplements and meal replacements to address specific patient needs, such as difficulty swallowing or taste alterations, is driving innovation.
• 3. Regional Expansion: Emerging markets in South Asia and the Pacific, with their increasing healthcare awareness and rising cancer burden, present significant growth opportunities.

Regional Analysis

• 1. Europe: Europe leads the market with its robust healthcare infrastructure and emphasis on holistic cancer care, including nutritional support.
• 2. South Asia and the Pacific: This region is the fastest-growing market, driven by an alarming rise in cancer cases and increasing healthcare awareness.
• 3. North America: With advanced healthcare systems and a high prevalence of cancer, North America remains a significant contributor to the market.

Recent Developments

• 1. Product Launch: In July 2022, Nestle introduced its first Foods for Special Medical Purposes (FSMP) for cancer patients in China, following a rigorous five-year regulatory approval process.
• 2. Innovative Funding: In January 2022, Faeth Therapeutics secured $47 million in a Series A financing round to advance clinical trials integrating nutrient control, drugs, and digital tools for cancer management.

Key Players The competitive Analysis of the oncology nutrition market includes prominent players such as:

• Aceto
• B. Braun Melsungen AG
• Baxter
• Fresenius Kabi AG
• Global Health Products, Inc.
• Hormel Foods Corporation
• Mead Johnson & Company, LLC
• Meiji Holdings Co., Ltd
• Nestle S.A.
• BioSig Technologies, Inc.
• Auris Health, Inc.

Market Segmentation The oncology nutrition market is segmented as follows:

• By Cancer Type: Head and Neck Cancers, Stomach and Gastrointestinal Cancers, Liver Cancer, Pancreatic Cancer, Esophageal Cancer, Lung Cancer, Breast Cancer, Blood Cancer, and Others.
• By End-use: Hospitals & Clinics, Home Care, and Others.
• By Region: North America, Europe, East Asia, South Asia & Oceania, Latin America, and the Middle East & Africa.

Table of Contents

1. Executive Summary

• 1.1. Global Oncology Nutrition Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2025
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Economic Overview
  • 2.6.1. World Economic Projections
• 2.7. PESTLE Analysis

3. Global Oncology Nutrition Market Outlook, 2019 - 2032

• 3.1. Global Oncology Nutrition Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2032
  • 3.1.1. Key Highlights
    • 3.1.1.1. Head and Neck Cancers
    • 3.1.1.2. Stomach and Gastrointestinal Cancers
    • 3.1.1.3. Liver Cancer
    • 3.1.1.4. Pancreatic Cancer
    • 3.1.1.5. Esophageal Cancer
    • 3.1.1.6. Lung Cancer
    • 3.1.1.7. Breast Cancer
    • 3.1.1.8. Blood Cancer
    • 3.1.1.9. Other Cancers
• 3.2. Global Oncology Nutrition Market Outlook, by End Use, Value (US$ Bn), 2019 - 2032
  • 3.2.1. Key Highlights
    • 3.2.1.1. Hospitals & Clinics
    • 3.2.1.2. Home Care
    • 3.2.1.3. Others
• 3.3. Global Oncology Nutrition Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
  • 3.3.1. Key Highlights
    • 3.3.1.1. North America
    • 3.3.1.2. Europe
    • 3.3.1.3. Asia Pacific
    • 3.3.1.4. Latin America
    • 3.3.1.5. Middle East & Africa

4. North America Oncology Nutrition Market Outlook, 2019 - 2032

• 4.1. North America Oncology Nutrition Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2032
  • 4.1.1. Key Highlights
    • 4.1.1.1. Head and Neck Cancers
    • 4.1.1.2. Stomach and Gastrointestinal Cancers
    • 4.1.1.3. Liver Cancer
    • 4.1.1.4. Pancreatic Cancer
    • 4.1.1.5. Esophageal Cancer
    • 4.1.1.6. Lung Cancer
    • 4.1.1.7. Breast Cancer
    • 4.1.1.8. Blood Cancer
    • 4.1.1.9. Other Cancers
• 4.2. North America Oncology Nutrition Market Outlook, by End Use, Value (US$ Bn), 2019 - 2032
  • 4.2.1. Key Highlights
    • 4.2.1.1. Hospitals & Clinics
    • 4.2.1.2. Home Care
    • 4.2.1.3. Others
• 4.3. North America Oncology Nutrition Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 4.3.1. Key Highlights
    • 4.3.1.1. Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 4.3.1.2. Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 4.3.1.3. Canada Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 4.3.1.4. Canada Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Oncology Nutrition Market Outlook, 2019 - 2032

• 5.1. Europe Oncology Nutrition Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2032
  • 5.1.1. Key Highlights
    • 5.1.1.1. Head and Neck Cancers
    • 5.1.1.2. Stomach and Gastrointestinal Cancers
    • 5.1.1.3. Liver Cancer
    • 5.1.1.4. Pancreatic Cancer
    • 5.1.1.5. Esophageal Cancer
    • 5.1.1.6. Lung Cancer
    • 5.1.1.7. Breast Cancer
    • 5.1.1.8. Blood Cancer
    • 5.1.1.9. Other Cancers
• 5.2. Europe Oncology Nutrition Market Outlook, by End Use, Value (US$ Bn), 2019 - 2032
  • 5.2.1. Key Highlights
    • 5.2.1.1. Hospitals & Clinics
    • 5.2.1.2. Home Care
    • 5.2.1.3. Others
• 5.3. Europe Oncology Nutrition Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 5.3.1. Key Highlights
    • 5.3.1.1. Germany Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 5.3.1.2. Germany Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 5.3.1.3. U.K. Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 5.3.1.4. U.K. Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 5.3.1.5. France Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 5.3.1.6. France Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 5.3.1.7. Italy Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 5.3.1.8. Italy Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 5.3.1.9. Turkey Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 5.3.1.10. Turkey Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 5.3.1.11. Russia Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 5.3.1.12. Russia Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 5.3.1.13. Rest of Europe Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 5.3.1.14. Rest of Europe Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Oncology Nutrition Market Outlook, 2019 - 2032

• 6.1. Asia Pacific Oncology Nutrition Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2032
  • 6.1.1. Key Highlights
    • 6.1.1.1. Head and Neck Cancers
    • 6.1.1.2. Stomach and Gastrointestinal Cancers
    • 6.1.1.3. Liver Cancer
    • 6.1.1.4. Pancreatic Cancer
    • 6.1.1.5. Esophageal Cancer
    • 6.1.1.6. Lung Cancer
    • 6.1.1.7. Breast Cancer
    • 6.1.1.8. Blood Cancer
    • 6.1.1.9. Other Cancers
• 6.2. Asia Pacific Oncology Nutrition Market Outlook, by End Use, Value (US$ Bn), 2019 - 2032
  • 6.2.1. Key Highlights
    • 6.2.1.1. Hospitals & Clinics
    • 6.2.1.2. Home Care
    • 6.2.1.3. Others
  • 6.2.2. BPS Analysis/Market Attractiveness Analysis
• 6.3. Asia Pacific Oncology Nutrition Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 6.3.1. Key Highlights
    • 6.3.1.1. China Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 6.3.1.2. China Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 6.3.1.3. Japan Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 6.3.1.4. Japan Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 6.3.1.5. South Korea Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 6.3.1.6. South Korea Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 6.3.1.7. India Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 6.3.1.8. India Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 6.3.1.9. Southeast Asia Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 6.3.1.10. Southeast Asia Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 6.3.1.11. Rest of Asia Pacific Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 6.3.1.12. Rest of Asia Pacific Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Oncology Nutrition Market Outlook, 2019 - 2032

• 7.1. Latin America Oncology Nutrition Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2032
  • 7.1.1. Key Highlights
    • 7.1.1.1. Head and Neck Cancers
    • 7.1.1.2. Stomach and Gastrointestinal Cancers
    • 7.1.1.3. Liver Cancer
    • 7.1.1.4. Pancreatic Cancer
    • 7.1.1.5. Esophageal Cancer
    • 7.1.1.6. Lung Cancer
    • 7.1.1.7. Breast Cancer
    • 7.1.1.8. Blood Cancer
    • 7.1.1.9. Other Cancers
• 7.2. Latin America Oncology Nutrition Market Outlook, by End Use, Value (US$ Bn), 2019 - 2032
  • 7.2.1.1. Hospitals & Clinics
  • 7.2.1.2. Home Care
  • 7.2.1.3. Others
  • 7.2.2. BPS Analysis/Market Attractiveness Analysis
• 7.3. Latin America Oncology Nutrition Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 7.3.1. Key Highlights
    • 7.3.1.1. Brazil Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 7.3.1.2. Brazil Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 7.3.1.3. Mexico Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 7.3.1.4. Mexico Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 7.3.1.5. Argentina Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 7.3.1.6. Argentina Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 7.3.1.7. Rest of Latin America Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 7.3.1.8. Rest of Latin America Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Oncology Nutrition Market Outlook, 2019 - 2032

• 8.1. Middle East & Africa Oncology Nutrition Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2032
  • 8.1.1. Key Highlights
    • 8.1.1.1. Head and Neck Cancers
    • 8.1.1.2. Stomach and Gastrointestinal Cancers
    • 8.1.1.3. Liver Cancer
    • 8.1.1.4. Pancreatic Cancer
    • 8.1.1.5. Esophageal Cancer
    • 8.1.1.6. Lung Cancer
    • 8.1.1.7. Breast Cancer
    • 8.1.1.8. Blood Cancer
    • 8.1.1.9. Other Cancers
• 8.2. Middle East & Africa Oncology Nutrition Market Outlook, by End Use, Value (US$ Bn), 2019 - 2032
  • 8.2.1. Key Highlights
    • 8.2.1.1. Hospitals & Clinics
    • 8.2.1.2. Home Care
    • 8.2.1.3. Others
  • 8.2.2. BPS Analysis/Market Attractiveness Analysis
• 8.3. Middle East & Africa Oncology Nutrition Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 8.3.1. Key Highlights
    • 8.3.1.1. GCC Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 8.3.1.2. GCC Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 8.3.1.3. South Africa Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 8.3.1.4. South Africa Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 8.3.1.5. Egypt Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 8.3.1.6. Egypt Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 8.3.1.7. Nigeria Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 8.3.1.8. Nigeria Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
    • 8.3.1.9. Rest of Middle East & Africa Oncology Nutrition Market by Cancer Type, Value (US$ Bn), 2019 - 2032
    • 8.3.1.10. Rest of Middle East & Africa Oncology Nutrition Market by End Use, Value (US$ Bn), 2019 - 2032
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Company Market Share Analysis, 2025
• 9.2. Competitive Dashboard
• 9.3. Company Profiles
  • 9.3.1. Aceto
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Therapy Portfolio
    • 9.3.1.3. Financial Overview
    • 9.3.1.4. Business Strategies and Development
  • 9.3.2. B. Braun Melsungen AG
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Therapy Portfolio
    • 9.3.2.3. Financial Overview
    • 9.3.2.4. Business Strategies and Development
  • 9.3.3. Baxter
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Therapy Portfolio
    • 9.3.3.3. Financial Overview
    • 9.3.3.4. Business Strategies and Development
  • 9.3.4. Fresenius Kabi AG
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Therapy Portfolio
    • 9.3.4.3. Financial Overview
    • 9.3.4.4. Business Strategies and Development
  • 9.3.5. Hormel Foods Corporation
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Therapy Portfolio
    • 9.3.5.3. Financial Overview
    • 9.3.5.4. Business Strategies and Development
  • 9.3.6. Mead Johnson & Company, LLC
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Therapy Portfolio
    • 9.3.6.3. Financial Overview
    • 9.3.6.4. Business Strategies and Development
  • 9.3.7. Meiji Holdings Co., Ltd
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Therapy Portfolio
    • 9.3.7.3. Financial Overview
    • 9.3.7.4. Business Strategies and Development
  • 9.3.8. Nestle S.A.
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Therapy Portfolio
    • 9.3.8.3. Financial Overview
    • 9.3.8.4. Business Strategies and Development
  • 9.3.9. BioSig Technologies, Inc.
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Therapy Portfolio
    • 9.3.9.3. Financial Overview
    • 9.3.9.4. Business Strategies and Development
  • 9.3.10. Auris Health, Inc.
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Therapy Portfolio
    • 9.3.10.3. Financial Overview
    • 9.3.10.4. Business Strategies and Development
  • 9.3.11. Others
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Therapy Portfolio
    • 9.3.11.3. Financial Overview
    • 9.3.11.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations